Natalio Krasnogor

GitLife Biotech is a pioneering deep-tech company at the forefront of synthetic biology, offering a robust bio-digital platform (CellRepo) to improve identification and traceability of engineered biological assets for improved intellectual property (IP) protection, proof of provenance, secure collaboration and enhanced traceability to alleviate biosecurity concerns. The solution consists of a digital version control platform combined robust DNA barcoding for traceability of biological assets. Our goal is to make biological IP as secure and manageable as digital IP, fostering scalability and trust in this rapidly evolving field. GitLife Biotech’s core offerings include: 1.CellRepo - Version Control Platform: Inspired by software development principles, our system manages iterations and variants of biological assets securely, enabling seamless collaboration and innovation. 2.Genosignatures - DNA Barcoding: Our proprietary tagging system ensures precise lineage tracking and traceability of biological assets. This technology enables compliance with regulatory standards while safeguarding IP. 3.Synthetic Biology Marketplace: GitLife’s online platform for secure sharing of biological assets will enable a market place where people can share open source or license proprietary biological assets all with full lineage and origin data. Our protocols cover 90% of the strains used in engineering biology and we are developing more all the time. See www.CellRepo.com for more information and to register. We are a Newcastle University spin out, co-founded with the venture builder Cambridge Future Tech Ltd.